CureVac N.V.

CureVac is a German biopharmaceutical company pioneering the use of messenger RNA (mRNA) technology for the development of vaccines and therapeutics. Founded in 2000 by Ingmar Hoerr, one of the early pioneers of mRNA science, CureVac was among the first companies to recognize mRNA’s potential to instruct the body to produce its own therapeutic proteins. The company’s research focuses on infectious diseases, oncology, and protein-based therapies.

Mission and Vision

Mission: To unlock the full potential of mRNA technology to create innovative medicines that protect and improve human health.
Vision: To make mRNA-based therapeutics a foundation of modern medicine through sustainable innovation and global collaboration.

Products and Services

Pipeline Programs:
- Infectious Diseases: Development of next-generation mRNA vaccines targeting influenza, COVID-19 (CV2CoV), and other viral pathogens.
- Oncology: Personalized mRNA cancer vaccines and tumor immunotherapies.
- Molecular Therapies: mRNA-based solutions for protein replacement and rare diseases.
Collaborations:
- Strategic partnerships with GSK (GlaxoSmithKline) for vaccine development.
- Collaboration with Tesla Grohmann Automation for automated mRNA production systems.

Growth and Innovation
CureVac was an early leader in mRNA science, filing foundational patents in the field before the global rise of mRNA vaccines. Although its first-generation COVID-19 vaccine candidate did not reach commercialization, the company has since developed second-generation mRNA platforms offering improved efficacy and stability. CureVac continues to focus on long-term applications of mRNA in oncology and protein therapy while expanding its manufacturing capabilities in Europe.

Global Impact
CureVac’s pioneering work laid the scientific foundation for today’s mRNA revolution. As one of the first companies to demonstrate that mRNA could be used safely and effectively in humans, CureVac has played a vital role in advancing global biotech innovation. Its ongoing partnerships with major pharmaceutical companies help accelerate vaccine accessibility and the development of next-generation mRNA technologies.